Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TOVAx
- Development stage
- Preclinical
- Lead developer
- PAI Life Sciences
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Parenteral
01
Overview
**TOVAx** is a preclinical recombinant protein vaccine program from PAI Life Sciences for prevention of onchocerciasis, also known as river blindness, caused by *Onchocerca volvulus*. The vaccine approach uses the parasite-derived recombinant antigens Ov-103 and Ov-RAL-2 to elicit protective antigen-specific immune responses, including antibody-mediated activity against infective larvae. PAI Life Sciences is developing the program with the Onchocerciasis Vaccine for Africa Initiative. ([pailifesciences.com](https://pailifesciences.com/pipeline/onchocerciasis/))
02
Targets
Ov-103 (Onchocerca volvulus Ov-103 antigen)Ov-RAL-2 (Onchocerca volvulus retinol-binding protein-like 2)
Beyond the preview
Go deeper on TOVAx.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TOVAx.